Nature Communications: transport of tumor selective nanopharmaceuticals via nano catalysts

Cancer as a human health killer, its incidence and mortality has been very high, tackling cancer has been an urgent problem In the current cancer treatment strategy, chemotherapy is one of the most commonly used means, but the high toxic chemotherapy drugs used in the conventional cancer chemotherapy have the effect on the whole body, causing strong toxic side effects, while the effect on the focus is greatly reduced In fact, side effects and multi cycle chemotherapy bring more pain to cancer patients, and even become the main cause of death of cancer chemotherapy patients Therefore, it is very important to develop the treatment strategy with high toxicity, high selectivity and safety for normal tissues and organs With the development of nanoscience and biotechnology, scientists have realized that the ecological microenvironment of tumor cells is quite different from that of normal cells, and tumor microenvironment has gradually become a research hotspot of tumor selective therapy The research team led by researcher Shi Jianlin and researcher Chen Yu of Shanghai Silicate Research Institute of Chinese Academy of Sciences put forward a new cancer treatment strategy of "nano catalysis medicine", which uses diversified, highly selective and highly specific catalytic reactions to realize the transformation of safe and non-toxic drugs into toxic substances in situ under the stimulation of tumor microenvironment, so as to achieve selective killing of tumor cells without The purpose of toxic and side effects on normal tissues Relevant research results have been published in the journal Nature communication with the title of tumor selective catalytic nanomedicine by nanocatalyst delivery Structure combination characteristics of dmsnsupports, FD NCS, and GFD NCS, And related TEM diagrams (source: nature Communications) In this work, the research team synthesized a kind of branched mesoporous silica nanoparticles as the carrier of drug transport system, successively loaded with ultra-small Fe3O4 nanoparticles and glucose oxidase, and constructed a new type of nano catalyst with chain catalysis The glucose oxidase in the nano catalyst is a highly active organic enzyme, and Fe3O4 nanoparticles is a highly efficient and stable Fenton reaction catalyst The catalyst uses the strong glucose raw materials and the micro acid metabolism environment in tumor cells to carry out the high-efficiency enzyme catalysis and chemical Fenton catalysis In the first step, glucose oxidase selectively catalyzes D-glucose in tumor to generate hydrogen peroxide and glucose endolipid Hydrogen peroxide, as the reactant of next chemical Fenton Catalytic reaction, is catalysed by Fe3O4 to generate highly toxic reactive oxygen species hydroxyl radical in acid condition The highly toxic hydroxyl radicals can induce the apoptosis of tumor cells, kill tumor cells and do not damage normal tissues and organs The results of animal experiments in vivo showed that the nano catalyst had no adverse effects on healthy mice within one month, indicating that it had good in vivo biosafety In vivo toxicity study of tumor bearing mice, it was found that the inhibition efficiency for 4T1 breast cancer and U87 brain glioma was 64.67% and 57.24% respectively, which indicated that the nano catalyst had better tumor killing and inhibition ability This work realizes the formation of toxic substances in situ by the safe and non-toxic nano medical catalyst under the stimulation of tumor microenvironment, which can kill tumor, and provides a new nano catalytic medical strategy for the future precise treatment of tumor Schematic diagram and photos of biodegradation process of gfdncs (source: nature Communications) paper link: https://www.nature.com/articles/s41467-017-00424-8? Wt.feed_name = subjects_catalysis